Xilio Therapeutics (XLO) Stock Overview
A clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
XLO Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Xilio Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.58 |
| 52 Week High | US$16.10 |
| 52 Week Low | US$6.47 |
| Beta | -0.13 |
| 1 Month Change | 0.65% |
| 3 Month Change | 7.80% |
| 1 Year Change | -31.72% |
| 3 Year Change | -80.05% |
| 5 Year Change | n/a |
| Change since IPO | -96.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| XLO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.7% | -1.6% | -0.8% |
| 1Y | -31.7% | 34.4% | 27.1% |
Return vs Industry: XLO underperformed the US Biotechs industry which returned 32.9% over the past year.
Return vs Market: XLO underperformed the US Market which returned 26.7% over the past year.
Price Volatility
| XLO volatility | |
|---|---|
| XLO Average Weekly Movement | 7.4% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: XLO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: XLO's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 76 | Rene Russo | xiliotx.com |
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company’s pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Xilio Therapeutics, Inc. Fundamentals Summary
| XLO fundamental statistics | |
|---|---|
| Market cap | US$50.50m |
| Earnings (TTM) | -US$31.30m |
| Revenue (TTM) | US$53.48m |
Is XLO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XLO income statement (TTM) | |
|---|---|
| Revenue | US$53.48m |
| Cost of Revenue | US$0 |
| Gross Profit | US$53.48m |
| Other Expenses | US$84.78m |
| Earnings | -US$31.30m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.23 |
| Gross Margin | 100.00% |
| Net Profit Margin | -58.52% |
| Debt/Equity Ratio | 0% |
How did XLO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/21 13:00 |
| End of Day Share Price | 2026/05/21 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Xilio Therapeutics, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Daina Graybosch | Leerink Partners LLC |